Literature DB >> 11350823

Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin.

E S Chen1, B M Greenlee, M Wills-Karp, D R Moller.   

Abstract

Because mouse strains susceptible to bleomycin, such as C57BL/ 6J, tend to produce T helper type 1 (Th1) cytokines in response to immune activation, we hypothesized that the inflammatory response to bleomycin is mediated, in part, by local production of the Th1 cytokine interferon-gamma (IFN-gamma). Consistent with this hypothesis, fibrosis-prone C57BL/6J and A/J mice demonstrated significantly elevated expression of IFN-gamma protein (by enzyme-linked immunosorbent assay) in bronchoalveolar lavage fluid at 24 h, and subsequently increased lung inflammation, weight loss, and mortality 10 d after intratracheal bleomycin administration compared with fibrosis-resistant BALB/c mice or saline control mice. To directly determine a role for IFN-gamma in bleomycin toxicity, we exposed C57BL/6J mice with a homozygous null mutation of the IFN-gamma gene (IFN-gamma[-/-]) and wild-type C57BL/6J mice to intratracheal bleomycin. IFN-gamma(-/-) mice demonstrated significantly lower parenchymal inflammation, weight loss, and mortality 10 d after 5 U/kg intratracheal bleomycin administration compared with control mice. At 3 wk after 1.5 U/kg bleomycin exposure, single lung collagen determined by hydroxyproline assay was significantly lower in IFN-gamma(-/-) mice compared with wild-type C57BL/6J mice. Together, these results suggest that IFN-gamma mediates, in part, bleomycin-induced pulmonary inflammation and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350823     DOI: 10.1165/ajrcmb.24.5.4064

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  38 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Characterization of Quin-C1 for its anti-inflammatory property in a mouse model of bleomycin-induced lung injury.

Authors:  Min He; Ni Cheng; Wei-wei Gao; Meng Zhang; Yue-yun Zhang; Richard D Ye; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

3.  Susceptibility of Hermansky-Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis.

Authors:  Lisa R Young; Rajamouli Pasula; Peter M Gulleman; Gail H Deutsch; Francis X McCormack
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-15       Impact factor: 6.914

4.  Interleukin-37 Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice.

Authors:  Yan Li; Qiaoyan Gao; Keye Xu; Xiao Peng; Xianli Yuan; Wenwen Jiang; Mingcai Li
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

5.  A site-specific genetic modification for induction of pluripotency and subsequent isolation of derived lung alveolar epithelial type II cells.

Authors:  Qing Yan; Yuan Quan; Huanhuan Sun; Xinmiao Peng; Zhengyun Zou; Joseph L Alcorn; Rick A Wetsel; Dachun Wang
Journal:  Stem Cells       Date:  2014-02       Impact factor: 6.277

6.  Fatty acid nitroalkenes inhibit the inflammatory response to bleomycin-mediated lung injury.

Authors:  Melissa L Wilkinson; Elena Abramova; Changjiang Guo; James G Gow; Alexa Murray; Adolf Koudelka; Veronika Cechova; Bruce A Freeman; Andrew J Gow
Journal:  Toxicol Appl Pharmacol       Date:  2020-09-12       Impact factor: 4.219

7.  Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice.

Authors:  Dachun Wang; John E Morales; Daniel G Calame; Joseph L Alcorn; Rick A Wetsel
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

8.  Inhibition of transforming growth factor-beta signalling attenuates interleukin (IL)-18 plus IL-2-induced interstitial lung disease in mice.

Authors:  S Segawa; D Goto; Y Yoshiga; M Sugihara; T Hayashi; Y Chino; I Matsumoto; S Ito; T Sumida
Journal:  Clin Exp Immunol       Date:  2010-01-19       Impact factor: 4.330

9.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3.

Authors:  Dianhua Jiang; Jiurong Liang; Jennifer Hodge; Bao Lu; Zhou Zhu; Shuang Yu; Juan Fan; Yunfei Gao; Zhinan Yin; Robert Homer; Craig Gerard; Paul W Noble
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent.

Authors:  Mark S Wilson; Satish K Madala; Thirumalai R Ramalingam; Bernadette R Gochuico; Ivan O Rosas; Allen W Cheever; Thomas A Wynn
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.